54103-36-5

Upstream product

• 554-12-1 propanoic acid methyl ester 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 105-37-3 Ethyl propionate 

Downstream Products

• 137795-09-6 3-(4-morpholinylmethyl)-5-ethyl-6-(4-methoxybenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 54103-42-3 1-(4-Methoxy-phenyl)-4,6-dimethyl-heptane-1,3,5-trione 
• 3343-80-4 (2-ethylbenzofuran-3-yl)(4-methoxyphenyl)methanone 
• 1477-19-6 benzarone 
• 3562-84-3 benzbromarone 

Relevant academic research and scientific papers

Lewis Acid-Catalyzed Synthesis of Benzofurans and 4,5,6,7-Tetrahydrobenzofurans from Acrolein Dimer and 1,3-Dicarbonyl Compounds

2,3-Disubstituted benzofurans were synthesized from acrolein dimer and 1,3-dicarbonyl compounds by using N-bromosuccinimide as an oxidizing agent. The method was used to synthesize two commercial drug molecules, benzbromarone and amiodarone. The proposed mechanism of the reaction involves a N-bromosuccinimide (NBS)-assisted autotandem catalysis with Lewis acid catalyst. To proof the proposed mechanism, an intermediate was isolated successfully, which can be converted to 4,5,6,7-tetrahydrobenzofurans.

HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE

Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. I

URAT1 inhibitor and its application

The invention discloses a URAT1 inhibitor compound and its application of the compound. The URAT1 inhibitor compound is the compound or its pharmaceutically acceptable salt shown in structure of Formula (I). The experiment shows that the compound provided

COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT

Provided are a compound as represented in formula (I), a pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and uses thereof. The compound as represented in formula (I) and the pharmaceutically acceptable salts thereof are used in the preparation of medicines for the treatment or prevention of hyperuricemia or gout by means of uric acid excretion.

URAT1 inhibitor for promoting uric acid excretion

The invention belongs to the field of medicinal chemistry, and in particular relates to a URT1 inhibitor for promoting uric acid excretion, which is a compound represented by the structure of the formula (I) or a pharmaceutically acceptable salt thereof. Experiments show that the compound provided by the invention has excellent inhibitory effect to hURAT1 transport uric acid in HEK293 transfectedcells and has a good application prospect in treatment of hyperuricemia or gout. The formula (I) is shown in the description.

Synthesis and biological evaluation of 3-alkyl-1,5-diaryl-1H-pyrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative activity

A series of novel 3-alkyl-1,5-diaryl-1H-pyrazoles were synthesized as combretastatin A-4 (CA-4) analogues and evaluated for antiproliferative activity against three human cancer cell lines (SGC-7901, A549 and HT-1080). Most of the target compounds displayed moderate to potent antiproliferative activity, and 7k was found to be the most potent compound. Structure-activity relationships indicated that compounds with a trimethoxyphenyl A-ring at the N-1 position of the pyrazole skeleton were more potent than those with the A-ring at the C-5 position. Tubulin polymerization and immunostaining experiments revealed that 7k potently inhibited tubulin polymerization and disrupted tubulin microtubule dynamics in a manner similar to CA-4. Computational modelling demonstrated that the binding of 7k to the colchicine binding site on microtubules may involve a similar mode as CA-4.

ANTI-GLAUCOMA COMPOSITIONS CONTAINING 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL- OR 6-PHENYLTHIO-2,3-DIHYDROPYRROLO-(1,2,3-DE)-1,4-BENZOXAZINES AND METHOD OF USE THEREOF

Antiglaucoma compositions containing 2-and 3-aminomethyl-6-arylcarbonyl-or 6-phenylthio-2,3-dihydropyrrolo-[1,2,3-de]-1,4-benzoxazines as the active component thereof and the method of use thereof in the treatment of glaucoma.

2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazines

2- and 3-Aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazines, useful as analgesic agents, are prepared either by reaction of a 2- or 3-aminomethyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine with an arylcarboxylic acid halide in the